Roche Holding AG (OTCMKTS:RHHBY) Short Interest Update

Roche Holding AG (OTCMKTS:RHHBY) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 2,782,461 shares, a decrease of 40.6% from the January 29th total of 4,684,288 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 5,239,296 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 5,239,296 shares, the short-interest ratio is presently 0.5 days. Approximately 0.0% of the company’s shares are sold short.

Institutional Trading of Roche

A number of hedge funds have recently made changes to their positions in the company. Curio Wealth LLC acquired a new position in shares of Roche in the 3rd quarter valued at approximately $25,000. Oakworth Capital Inc. bought a new stake in shares of Roche in the third quarter worth $57,000. First Horizon Advisors Inc. increased its stake in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after buying an additional 826 shares during the last quarter. Salomon & Ludwin LLC boosted its stake in Roche by 256.6% during the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after acquiring an additional 2,053 shares during the last quarter. Finally, Atlas Capital Advisors Inc. bought a new position in Roche during the 4th quarter valued at $192,000.

Roche Trading Up 0.9%

Shares of RHHBY opened at $59.55 on Monday. Roche has a 12 month low of $34.75 and a 12 month high of $60.85. The stock’s 50-day moving average is $55.49 and its two-hundred day moving average is $48.10. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38.

Wall Street Analyst Weigh In

Several research analysts have weighed in on RHHBY shares. Morgan Stanley restated an “underweight” rating on shares of Roche in a report on Wednesday, February 4th. HSBC reaffirmed a “buy” rating and set a $57.00 price target on shares of Roche in a research report on Wednesday, December 10th. JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a report on Monday, December 8th. Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, Zacks Research upgraded Roche from a “strong sell” rating to a “hold” rating in a report on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Roche has a consensus rating of “Hold” and an average price target of $57.00.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.